Balyasny Asset Management L.P. Increases Position in LivaNova PLC (NASDAQ:LIVN)

Balyasny Asset Management L.P. raised its position in LivaNova PLC (NASDAQ:LIVN - Free Report) by 85.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 437,878 shares of the company's stock after buying an additional 201,682 shares during the quarter. Balyasny Asset Management L.P. owned 0.81% of LivaNova worth $20,278,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in LIVN. Bayesian Capital Management LP acquired a new position in shares of LivaNova in the fourth quarter worth approximately $218,000. BNP Paribas Financial Markets grew its stake in LivaNova by 22.8% in the 4th quarter. BNP Paribas Financial Markets now owns 34,185 shares of the company's stock valued at $1,583,000 after purchasing an additional 6,340 shares during the period. Algert Global LLC grew its stake in LivaNova by 13.0% in the 4th quarter. Algert Global LLC now owns 118,713 shares of the company's stock valued at $5,498,000 after purchasing an additional 13,696 shares during the period. Aristeia Capital L.L.C. bought a new position in LivaNova in the 4th quarter valued at $3,395,000. Finally, AXA S.A. bought a new position in LivaNova in the 4th quarter valued at $1,662,000. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Trading Down 2.0%

Shares of NASDAQ:LIVN traded down $0.91 during trading on Tuesday, reaching $44.32. The company's stock had a trading volume of 152,702 shares, compared to its average volume of 638,517. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $2.42 billion, a PE ratio of 105.52 and a beta of 0.84. LivaNova PLC has a 12 month low of $32.48 and a 12 month high of $63.57. The firm's 50 day simple moving average is $37.98 and its two-hundred day simple moving average is $45.04.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Needham & Company LLC restated a "buy" rating and issued a $64.00 price objective on shares of LivaNova in a research note on Tuesday. Mizuho cut their price target on LivaNova from $70.00 to $60.00 and set an "outperform" rating for the company in a research note on Wednesday, February 26th. StockNews.com downgraded LivaNova from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 8th. Robert W. Baird increased their price target on LivaNova from $55.00 to $61.00 and gave the stock an "outperform" rating in a research note on Thursday, May 8th. Finally, Barclays dropped their price target on shares of LivaNova from $56.00 to $55.00 and set an "equal weight" rating on the stock in a research note on Thursday, May 8th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $59.17.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.